Vantage logo

No Ameera glory for Sanofi

Amcenestrant flunks the long-delayed Ameera-3 trial in ER-positive Her2-negative breast cancer, so how much blame can be put on poor study design?

Vantage logo

Delays hit Sanofi

The Ameera-3 readout gets pushed back again, while fitusiran’s filing will not happen until 2024.